Helix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date
10 August 2013 - 12:45AM
Marketwired
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a
biopharmaceutical company developing drug candidates for the
prevention and treatment of cancer, today announced that it has
received the Toronto Stock Exchange's approval of its proposal to
extend the expiry date of the 2010 Warrants (as defined below) by
eighteen months, from August 5, 2013 at 5:00 p.m. (Toronto time)
(the "
Current Expiry Date") to February 5,
2015 at 5:00 p.m. (Toronto time) (the "
Amended
Expiry Date"). Helix also received approval to increase the
exercise price for the 2010 Warrants from $3.40 to $4.15, effective
from and after the Current Expiry Date (together with the extension
of the expiry date, the "
Amendments"). Helix
has not amended any other provision of the 2010 Warrants, and none
of the 2010 Warrants is held directly or indirectly by an insider
of Helix. The Amendments were effective as of 5:00 p.m. on August
5, 2013.
The 2010 Warrants were issued as part of a private placement
completed by Helix on August 6, 2010, pursuant to which Helix
issued 4,530,000 units at a subscription price of $2.43 per unit.
Each unit consisted of one common share and one common share
purchase warrant (each a "2010 Warrant"),
with each 2010 Warrant common entitling the holder to purchase,
subject to adjustment, one common share at a price of $3.40 until
the Current Expiry Date.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's
product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and
Uncertainties This news release contains certain
forward-looking statements and information (collectively,
"forward-looking statements") within the meaning of applicable
Canadian securities laws. Forward-looking statements, which may be
identified by words including, without limitation, "will" and other
similar expressions, are intended to provide information about
management's current plans and expectations regarding future
operations.
Although Helix believes that the expectations reflected in such
forward-looking statements are reasonable, such statements involve
risks and uncertainties that may cause actual results or events to
differ materially from those anticipated and no assurance can be
given that these expectations will be realized, and undue reliance
should not be placed on such statements. Risk factors that could
cause actual results or events to differ materially from the
forward-looking statements include, without limitation, those
described in Helix's Annual Information Form, including under the
headings "Forward-Looking Statements" and "Risk Factors", filed
with the Canadian Securities Administrators at www.sedar.com
(together, the "Helix Risk Factors"). Certain material factors or
assumptions are applied in making the forward-looking statements,
including, without limitation, the Helix Risk Factors will not
cause Helix's actual results or events to differ materially from
the forward-looking statements.
Forward-looking statements and information are based on the
beliefs, assumptions and expectations of Helix's management on the
date of this news release, and Helix does not assume any obligation
to update any forward-looking statement or information should those
beliefs, assumptions or expectations, or other circumstances
change, except as required by law.
Investor Relations: Helix BioPharma Corp. Tel: 905
841-2300 Email: ir@helixbiopharma.com
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024